Progresses on active targeting liposome drug delivery systems for tumor therapy

Liposome is an ideal drug carrier with many advantages such as excellent biocompatibility, non-immunogenicity, and easy functionalization, and has been used for the clinical treatment of many diseases including tumors. For the treatment of tumors, liposome has some passive targeting capability, but...

Full description

Saved in:
Bibliographic Details
Published in:Sheng wu yi xue gong cheng xue za zhi 2022-06, Vol.39 (3), p.633-638
Main Authors: Zhang, Manyu, Lou, Chenxi, Cao, Aoneng
Format: Article
Language:Chinese
Subjects:
Drug Carriers - therapeutic use
Drug Delivery Systems
Humans
Liposomes - therapeutic use
Neoplasms - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liposome is an ideal drug carrier with many advantages such as excellent biocompatibility, non-immunogenicity, and easy functionalization, and has been used for the clinical treatment of many diseases including tumors. For the treatment of tumors, liposome has some passive targeting capability, but the passive targeting effect alone is very limited in improving the drug enrichment in tumor tissues, and active targeting is an effective strategy to improve the drug enrichment. Therefore, active targeting liposome drug-carriers have been extensively studied for decades. In this paper, we review the research progresses on active targeting liposome drug-carriers based on the specific binding of the carriers to the surface of tumor cells, and summarize the opportunities, challenges and future prospects in this field.
ISSN:1001-5515
DOI:10.7507/1001-5515.202110067